Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Additional Locations, Minnesota Clinical Trials

A listing of Additional Locations, Minnesota clinical trials actively recruiting patient volunteers.

RESULTS

Found (40) clinical trials

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of adavosertib (AZD1755 [MK-1775]) administered on days 1 through 5 every 21 days, in combination with oral irinotecan (irinotecan hydrochloride), to children with recurrent or refractory solid tumors. II. To define and describe the toxicities ...

Phase

2.98 miles

Learn More »

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

PRIMARY OBJECTIVES: I. Determine the tolerability, and define and describe the toxicities of nivolumab administered as a single agent in children with relapsed or refractory solid tumors at the adult recommended dose of 3 mg/kg. II. Determine if systemic nivolumab exposure in children is similar to the systemic exposure in ...

Phase

2.98 miles

Learn More »

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

The purpose of this study is to determine the maximum tolerated dose (MTD) of Pregnyl when given in combination with standard immunosuppressive therapy in pediatric and adult patients with high-risk (Arm 1) or refractory/dependent (Arm 2) aGVHD.

Phase

2.98 miles

Learn More »

Pepinemab in Treating Younger Patients With Recurrent Relapsed or Refractory Solid Tumors

PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of pepinemab (VX15/2503) administered as an intravenous infusion every 14 days to children with recurrent or refractory solid tumors. (Part A) II. To define and describe the toxicities of VX15/2503 administered on this schedule. (Parts ...

Phase

2.98 miles

Learn More »

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

For patients who do not find relief from other modes of therapy, autologous serum tears have been used as an alternative therapy since the mid-1980s. Limitations such as the need for periodic blood draws, the lack of standardization in the preparation of AST and platelet-enriched plasma tears, the unknown shelf ...

Phase

2.98 miles

Learn More »

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

Recurrent FSGS is a risk factor for graft lost: Recurrence of FSGS can occur rapidly, within minutes of transplantation, and can lead to immediate onset of proteinuria and graft dysfunction. Recurrent FSGS is definitively diagnosed with a kidney biopsy. Early kidney biopsies in recurrent FSGS often demonstrate only extensive foot ...

Phase

2.98 miles

Learn More »

Isometric Intervention for Lateral Elbow Tendinopathy

Participants will be randomized into two different groups in 10 participant blocks, meaning after every 10 participants eligible and completing the study, there will be 5 participants assigned to each group. Group 1 will complete a protocol with 10 sets of 10 second isometric holds followed by 10 second rest ...

Phase

2.98 miles

Learn More »

Ketamine and Prolonged Exposure in PTSD

Study location: Minneapolis VA Medical Center The study is an open-label interventional study designed to inform and strengthen the feasibility of protocol implementation on sub-anesthetic doses of intravenous Ketamine as augmenting strategy of standardized, manually-driven Prolonged Exposure therapy in PTSD. Timeline: Eligible individuals can expect their participation to last up ...

Phase

3.93 miles

Learn More »

Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

Treatment will consist of 4 main phases: Remission Induction, Consolidation, Reinduction, and Maintenance. High risk patients will receive a reintensification phase prior to transplant in first remission. REMISSION INDUCTION: Chemotherapy will be given in an attempt to induce the participant's leukemia into remission. Drugs given are intrathecal triple drug treatment ...

Phase

8.07 miles

Learn More »

IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

This pilot study will evaluate use of IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated MDS, CMML and O-AML. 765IGF-MTX at a dose of 0.20 to 2.5 equivalents per kg is administered as an IV infusion over 1.5 hours on days 1, 8 and 15 of a 28 day ...

Phase

9.52 miles

Learn More »